HeartBeam (NASDAQ: BEAT) announced the initiation of a pilot study evaluating its investigational on-demand 12-lead ECG ...
The study will enrol around 50 high-risk coronary artery disease patients whose resting ECGs show no signs of ischemia.
HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results highlighted by the launch of its initial commercial partnerships in key U.S. markets, progress in its heart ...
(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced the initiation of a pilot study evaluating its novel on-demand ...
AliveCor has spent years battling with Apple over the market for consumer heart monitoring technology. Now it’s hoping to make its imprint on professional health care with its new device, which ...
SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it ...
New device clearances: FDA granted 510(k) clearance to Biozen’s cuffless BP1000 blood pressure device, while HeartBeam began a pilot study of its on-demand 12-lead ECG patch. Faster Medicare coverage: ...
Vienna, Austria- 31 March 2025 - While everybody’s heart has an absolute chonological age (as old as that person is), hearts also have a theoretical ‘biological’ age1 that is based on how the heart ...